BridgeBio Oncology Therapeutics Inc. (BBOT) Statistics & Valuation Metrics - Stocknear

BridgeBio Oncology Therap...

NASDAQ: BBOT · Real-Time Price · USD
11.47
-0.23 (-1.97%)
At close: Sep 29, 2025, 3:59 PM
11.35
-1.05%
After-hours: Sep 29, 2025, 07:29 PM EDT

BridgeBio Oncology Therapeutics Statistics

Share Statistics

BridgeBio Oncology Therapeutics has n/a shares outstanding. The number of shares has increased by 0.14% in one year.

n/a
0.14%
0%
n/a
447.85K
6,362
3.08%

Short Selling Information

The latest short interest is 78.08K, so 0% of the outstanding shares have been sold short.

78.08K
n/a
n/a
1

Valuation Ratios

The PE ratio is 22.98 and the forward PE ratio is -5.2. BridgeBio Oncology Therapeutics's PEG ratio is 0.

22.98
-5.2
0
n/a
0.93
-228.69
0
Financial Ratio History

Enterprise Valuation

BridgeBio Oncology Therapeutics has an Enterprise Value (EV) of 172.98M.

0
22.76
-226.47
-226.47

Financial Position

The company has a current ratio of 10.4, with a Debt / Equity ratio of 0.

10.4
10.4
0
n/a
n/a
0

Financial Efficiency

Return on Equity is 4.03% and Return on Invested Capital is -0.3%.

4.03%
3.91%
-0.3%
n/a
n/a
undefined
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by 9.76% in the last 52 weeks. The beta is -0.23, so BridgeBio Oncology Therapeutics's price volatility has been lower than the market average.

-0.23
9.76%
10.33
10.65
57.05
206,680

Income Statement

n/a
n/a
-584K
7.6M
7.6M
7.6M
0.46
Full Income Statement

Balance Sheet

The company has 1.7M in cash and 0 in debt, giving a net cash position of 1.7M.

1.7M
n/a
n/a
-3.73M
197.39M
-1.75M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -763.82K and capital expenditures 0, giving a free cash flow of -763.82K.

-763.82K
n/a
-763.82K
-0.05
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

BBOT does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
4.35%
-0.44%
Dividend Details

Analyst Forecast

The average price target for BBOT is $25, which is 118% higher than the current price. The consensus rating is "Buy".

$25
118%
Buy
4
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
10.8
-5.84%

Scores

68.79
2